Fosgonimeton

Fosgonimeton
Legal status
Legal status
  • Investigational
Identifiers
  • [4-[(2S)-3-[[(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] dihydrogen phosphate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC27H45N4O8P
Molar mass584.651 g·mol−1
3D model (JSmol)
  • CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N
  • InChI=1S/C27H45N4O8P/c1-4-6-8-12-24(33)30-22(18-20-13-15-21(16-14-20)39-40(36,37)38)26(34)31-25(19(3)5-2)27(35)29-17-10-7-9-11-23(28)32/h13-16,19,22,25H,4-12,17-18H2,1-3H3,(H2,28,32)(H,29,35)(H,30,33)(H,31,34)(H2,36,37,38)/t19-,22-,25-/m0/s1
  • Key:MBYDCPOKVKDSFD-JTJYXVOQSA-N

Fosgonimeton is an investigational new drug that is being evaluated to treat neurodegenerative diseases such as Alzheimer's and Parkinson's disease.[1] It is a pro-drug of the active metabolite dihexa. Dihexa in turn binds to the hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met.[2][3]

References

  1. ^ "Fosgonimeton - Athira Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Johnston JL, Reda SM, Setti SE, Taylor RW, Berthiaume AA, Walker WE, et al. (March 2023). "Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia". Neurotherapeutics. 20 (2): 431–451. doi:10.1007/s13311-022-01325-5. PMC 10121968. PMID 36538176.
  3. ^ Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, et al. (July 2024). "Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease". Neurotherapeutics. 21 (4) e00350. doi:10.1016/j.neurot.2024.e00350. PMC 11067346. PMID 38599894.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.